The Missing Element: Lithium's Role in Alzheimer's Pathology

The Missing Element: Why Lithium is Being Recognized as an Essential Endogenous Factor in Alzheimer's Pathology

For decades, the pursuit of an Alzheimer's cure has been dominated by a single, high-stakes strategy: clearing amyloid plaques. Billions of dollars have been poured into developing monoclonal antibodies like aducanumab, lecanemab, and donanemab. While these drugs successfully remove amyloid, their clinical impact on day-to-day cognition is often debated, and they come with risks of brain swelling and bleeding.

But what if we have been looking at the problem through the wrong lens? What if the pathology of Alzheimer's Disease is not just a story of toxicity caused by what is present, but a crisis of deficiency caused by what is missing?

Emerging evidence indicates that Alzheimer’s disease may be influenced, at least in part, by the depletion or dysregulation of a critical endogenous trace element: lithium. Historically categorized predominantly as a psychopharmacological agent for the treatment of bipolar disorder, lithium is currently being reconsidered as a potentially essential micronutrient for brain homeostasis. New data indicates that its deficiency may be a root cause of the disease and restoring it could outperform the newest FDA-approved drugs in specific cognitive domains.

Is Alzheimer’s a Deficiency Disease?

Large-scale population studies in Denmark, Japan, and the United States (Texas) had already revealed a startling pattern: regions with naturally lower levels of lithium in drinking water exhibited significantly higher rates of dementia and Alzheimer's mortality. While these findings strongly suggested that environmental lithium deficiency might be a risk factor, the biological mechanism linking trace levels of this element to neurodegeneration remained unclear.

That changed with a seminal study published in 2025 by researchers at Harvard Medical School. Moving beyond population data, the team analyzed post-mortem human brain tissue to determine if this deficiency existed at the organ level. They measured 27 abundant and trace metals in the brains of individuals with Alzheimer's and Mild Cognitive Impairment.

The results confirmed the epidemiological suspicion with high precision: Lithium was the only metal significantly reduced in the prefrontal cortex of these patients compared to cognitively intact controls. This confirmed that the deficiency is not just environmental, but intrinsic to the pathology.

The study elucidated a specific mechanism underlying this loss, referred to as “Amyloid Sequestration.”

• The "Theft": In this process lithium cations exhibit a chemical affinity for amyloid plaques. These plaques function analogously to absorbent matrices, binding lithium and effectively sequestering it away from physiologically active neural tissue.
• Functional Deficiency: This sequestration results in a localized lithium deficiency within neurons. In mouse models, experimental induction of this lithium depletion led to a rapid exacerbation of amyloid plaque deposition, increased accumulation of hyperphosphorylated tau (neurofibrillary tangles), and pronounced loss of synaptic structures and myelin.
• Vicious Cycle: The progressive depletion of bioavailable lithium compromises microglial-mediated clearance of amyloid, thereby diminishing the brain’s capacity to remove these pathological aggregates. This impairment establishes a positive feedback loop in which reduced amyloid clearance promotes further amyloid accumulation and exacerbation of neuropathology.

How Lithium Protects the Brain

The question arises as to why the brain demonstrates such a marked dependence on this element. Current scientific evidence suggests that lithium acts as a pleiotropic pharmacological agent, modulating multiple pathological signaling pathways in parallel rather than exerting its effects through a single, highly specific molecular target, as is typical for monoclonal antibodies. One of the principal mechanisms described is the inhibition of glycogen synthase kinase‑3 beta (GSK‑3β). In Alzheimer’s disease, GSK‑3β activity is upregulated, thereby promoting the overproduction of amyloid-β peptides and the hyperphosphorylation and subsequent aggregation of Tau proteins into neurofibrillary tangles. By inhibiting GSK‑3β, lithium interferes with these upstream pathogenic processes, effectively attenuating their downstream consequences.

Furthermore, research indicates that lithium stabilizes dysregulated calcium signaling in the endoplasmic reticulum. It modulates the IP_3 receptor, preventing the excessive calcium release that leads to neuronal death and synaptic dysfunction. Additionally, lithium enhances autophagy (the cell's waste disposal system), helping to clear toxic protein aggregates, and stimulates the production of BDNF (Brain-Derived Neurotrophic Factor), which promotes the birth of new neurons.

Lithium vs. New Drugs: What the Data Shows

While the biological mechanisms are compelling, the clinical data is even more provocative. A 2024 network meta-analysis compared the efficacy of lithium against anti-amyloid drugs (donanemab, lecanemab, and aducanumab). The results challenged the current pharmaceutical hierarchy. Superior Cognitive Efficacy: On the Mini-Mental State Examination (MMSE), lithium significantly outperformed aducanumab, donanemab, and placebo. Comparable Results: On the ADAS-Cog scale, lithium’s efficacy matched that of the new antibody drugs, confirming it as a potent intervention. Safety Profile: While donanemab and lecanemab were significantly less tolerable and acceptable than placebo due to adverse events, lithium did not differ significantly from placebo in tolerability.

This analysis suggests that low-dose lithium may offer a safer and potentially more effective alternative for preserving global cognition than the high-cost monoclonal antibodies currently dominating the market.

Optimizing Delivery to the Brain

A critical challenge in translating these benefits to patients has been the blood-brain barrier and the specific chemical properties of lithium salts. The standard psychiatric form, Lithium Carbonate, easily ionizes and gets trapped by the amyloid plaques (the sequestration effect described by the Harvard team), reducing its bioavailability to neurons.

In the search for optimization, Lithium Orotate (LiO) has emerged as a promising alternative formulation (PACHOLKO; BEKAR, 2021). Unlike the carbonate form, Lithium Orotate shows reduced ionization. This chemical property allows it to bypass amyloid sequestration, ensuring it reaches the neurons where it is needed.

Conclusion: A New Era of Precision Nutrition

The recognition of lithium not merely as a drug, but as an essential endogenous factor depleted by Alzheimer's pathology, represents a massive paradigm shift.

The evidence suggests that individuals with "amyloid sequestration" suffer from a functional brain deficiency of lithium. By utilizing advanced formulations like Lithium Orotate or microdose strategies that bypass metabolic barriers, we may be able to restore brain homeostasis. This approach provides a scientifically substantiated, accessible, and comparatively safer strategy, repositioning lithium from a peripheral role in psychiatry to a central component in the prevention of neurodegenerative disorders.

 

References

1. Aron, Liviu, Zhen Kai Ngian, Chenxi Qiu, et al. 2025. “Lithium Deficiency and the Onset of Alzheimer’s Disease.” Nature 645 (8081): 712–21. https://doi.org/10.1038/s41586-025-09335-x.
2. De-Paula, Vanessa De Jesus R., Marcia Radanovic, and Orestes Vicente Forlenza. 2025. “Lithium and Neuroprotection: A Review of Molecular Targets and Biological Effects at Subtherapeutic Concentrations in Preclinical Models of Alzheimer’s Disease.” International Journal of Bipolar Disorders 13 (1): 16. https://doi.org/10.1186/s40345-025-00386-7.
3. Fajardo, Val Andrew, Val Andrei Fajardo, Paul J. LeBlanc, and Rebecca E.K. MacPherson. 2017. “Examining the Relationship between Trace Lithium in Drinking Water and the Rising Rates of Age-Adjusted Alzheimer’s Disease Mortality in Texas.” Journal of Alzheimer’s Disease 61 (1): 425–34. https://doi.org/10.3233/JAD-170744.
4. Guilliot, Solene, Serge Gauthier, Jacques Touchon, and Maria E. Soto. 2023. “Lithium, a Treatment Option for Alzheimer’s Disease? A Review of Existing Evidence and Discussion on Future Perspectives.” Journal of Alzheimer’s Disease 96 (2): 473–82. https://doi.org/10.3233/JAD-230568.
5. Kessing, Lars Vedel, Thomas Alexander Gerds, Nikoline Nygård Knudsen, et al. 2017. “Association of Lithium in Drinking Water With the Incidence of Dementia.” JAMA Psychiatry 74 (10): 1005. https://doi.org/10.1001/jamapsychiatry.2017.2362.
6. Muronaga, Masaaki, Takeshi Terao, Kentaro Kohno, Hirofumi Hirakawa, Toshihiko Izumi, and Masaki Etoh. 2022. “Lithium in Drinking Water and Alzheimer’s Dementia: Epidemiological Findings from National Data Base of Japan.” Bipolar Disorders 24 (8): 788–94. https://doi.org/10.1111/bdi.13257.
7. Pacholko, Anthony G., and Lane K. Bekar. 2021. “Lithium Orotate: A Superior Option for Lithium Therapy?” Brain and Behavior 11 (8): e2262. https://doi.org/10.1002/brb3.2262.
8. Shen, Yanxin, Meng Zhao, Panpan Zhao, et al. 2024. “Molecular Mechanisms and Therapeutic Potential of Lithium in Alzheimer’s Disease: Repurposing an Old Class of Drugs.” Frontiers in Pharmacology 15 (July): 1408462. https://doi.org/10.3389/fphar.2024.1408462.
9. Shim, Seong Sool, Ken Berglund, and Shan Ping Yu. 2023. “Lithium: An Old Drug for New Therapeutic Strategy for Alzheimer’s Disease and Related Dementia.” Neurodegenerative Diseases 23 (1–2): 1–12. https://doi.org/10.1159/000533797.
10. Singulani, Monique Patricio, Ana Flávia Fernandes Ferreira, Paulina Sepúlveda Figueroa, et al. 2024. “Lithium and Disease Modification: A Systematic Review and Meta-Analysis in Alzheimer’s and Parkinson’s Disease.” Ageing Research Reviews 95 (March): 102231. https://doi.org/10.1016/j.arr.2024.102231.
11. Terao, Itsuki, and Wakako Kodama. 2024. “Comparative Efficacy, Tolerability and Acceptability of Donanemab, Lecanemab, Aducanumab and Lithium on Cognitive Function in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis.” Ageing Research Reviews 94 (February): 102203. https://doi.org/10.1016/j.arr.2024.102203.